AusBiotech Invest

Event Handbook

INVEST in HEALTH

Crown Towers
MELBOURNE
21 Oct 2025

@AusBiotech Invest 2025
#AusBiotechInvest2025
#ABI25

www.ausbiotechinvest.com

Host State Partner

VICTORIA State Government

Victoria, where government is your partner for success

VICTORIA
State Government

Melbourne, Victoria is a highly sought-after destination by global and local medical technology and pharmaceutical companies.

We offer a cost-competitive environment, access to specialist R&D and manufacturing capabilities, strong collaborative networks and an innovation culture, supported by government and private investment making it an ideal location for companies working to scale their innovation to global growth markets — all in one of the world's most liveable cities.

Together with our mature investment ecosystem and experience in working with early stage and commercial companies, the Victorian Government is keen to facilitate opportunities to drive investment in translation, research, innovation and commercialisation outcomes.

Find out how the Victorian Government can work with you to transform your idea or discovery into a market-ready product.

djsir.vic.gov.au/health-tech

Image courtesy of DJSIR/ Peter Casamento

Welcome

To AusBiotech Invest 2025

On behalf of AusBiotech, we are delighted to welcome you to AusBiotech Invest 2025, Australia's premier life sciences investment conference.

This year's theme, Invest in Health, reflects the strength, confidence and momentum of Australia's life sciences sector as it continues to mature and attract growing global attention. The companies and investors gathered here today represent a thriving ecosystem built on innovation, commercial focus, and meaningful collaboration and one that is rapidly evolving from science to scale.

As Australia's national advocate for life sciences, AusBiotech supports over 3,000 members through policy leadership, connection, and capability building. Our mission is to help breakthrough companies become great businesses by supporting the companies that drive health and medical breakthroughs, improve health outcomes, and create economic value for Australia and beyond.

Through AusBiotech Invest and our broader investment programs, we connect investors with curated, high-quality, investor-ready Australian companies across every stage of growth, from early ventures seeking seed funding to established firms pursuing scale and global markets. Each company here today represents a small part of Australia's total globally investible life sciences pipeline.

Australia's biotechnology and medical technology industries are scaling and maturing at pace, with close to 1,600 companies driving innovation nationwide. Between 2017 and 2025, the combined market capitalisation has risen from $50 billion to more than $250 billion, supported by consistent growth in earnings, exports and confidence from global investors and partners.

This momentum reflects a sector that is both resilient and globally competitive. Australian life science companies are forming international partnerships, building commercial traction, and demonstrating that our ecosystem can deliver at global scale.

AusBiotech Invest 2025 brings this to life with a concentrated day of investor access, curated deal flow, and strategic conversations that drive outcomes. It is a forum designed for confidence, efficiency and momentum, showcasing more than 20 Australian companies and creating meaningful connections between innovators, investors, and partners.

We extend our sincere thanks to our Host State Partner, the Victorian Government, and to our sponsors, presenting companies, speakers, and attendees for supporting this event and for your shared commitment to growing Australia's life sciences capability and capital base.

As you engage today, I hope you'll see the opportunity before us — to build not just great science, but globally investable businesses. Together we can strengthen Australia's position as a trusted hub for innovation, talent and capital.

Warm regards,
Rebekah Cassidy, AusBiotech CEO
Kerri Lee Sinclair, AusBiotech Head of Investment

Rebekah Cassidy
Chief Executive Officer
AusBiotech

Kerri Lee Sinclair
Head of Investment
AusBiotech

Invest Program 2025

9:00 AM - 9:20 AM	WELCOME & OFFICIAL OPENING

Welcome to Country: **Uncle Ian Hunter**, Wurundjeri Elder

Rebekah Cassidy, Chief Executive Officer, AusBiotech

The Hon. Danny Pearson, Minister for Economic Growth, Jobs and Minister for Finance, Victorian Government

9:20 AM - 9:45 AM	**FIRESIDE CHAT:** Smarter trials, stronger returns: Navigating biotech's clinical frontier

Explore how global trends, smarter planning, and emerging technologies are reshaping clinical development. IQVIA Biotech shares insights on AI-driven trial acceleration, Phase II outcomes, and innovative funding approaches — from partnerships to structured deals — helping investors and biotech leaders maximise value in a capital-constrained market.

Moderator: **Sarah Meibusch**, Partner, OneVentures

Speaker: **Megan Hooton,** President, IQVIA Biotech

9:45 AM - 10:35 AM	COMPANY PRESENTATIONS

Chair: **Kerri Lee Sinclair**, Head of Investment, AusBiotech

Prescient Therapeutics Ltd - James McDonnell, *Chief Executive Officer*
Goliver Australia Pty - Sami Bou-antoun, *Chief Executive Officer*
BiomeBank - Samuel Costello, *Chief Executive Officer & Co-Founder*
Terra Australis Pharmaceuticals Pty Ltd - Todd Robinson, *Chairman*
Avecho Biotechnology - Paul Gavin, *Chief Executive Officer*

Q&A

10:35 AM - 11:05 AM	MORNING TEA

11:05 AM - 12:00 PM	COMPANY PRESENTATIONS

Chair: **Rosanne Hyland**, Deputy Chief Executive Officer, AusBiotech

Chimeric Therapeutics - Rebecca McQualter, *Chief Executive Officer*
S2n.bio - Brendon Boot, *Chief Executive Officer*
Haemalogix Ltd - Alan Liddle, *Executive Director*
Humble Bee Bio Pty - Bridgit Hawkins, *Chief Executive Officer*
BlinkLab Ltd - Brian Leedman, *Chairman*

Q&A

12:00 PM - 12:30 PM	**PANEL:** Building Australia's future life sciences capital stack: Repeatable success stories

Australia produces world-class science, but our capital stack is uneven, surprisingly strong at seed and translation, thin in Series A/B, and shallow at the growth end. Other global hubs once faced the same challenge, in particular, Israel, the UK, Switzerland and Singapore. Each found their own ways to solve it and now have strong capital markets funding innovation. This panel brings together leading investors, corporates, and financiers to explore what Australia must build locally, what we should rely on globally, and how to ensure our companies scale at home while still connecting to global capital required to catalyse health outcomes.

Moderator: **Kerri Lee Sinclair**, Head of Investment, AusBiotech

Panellists

Medard Fischer, VP Strategic Investments Cochlear R&D, Cochlear

Rowena Gracey, Director, ARCHIMED

Sarah Meibusch, Partner, OneVentures

Chris Nave, Founding Partner & Managing Director, Brandon Capital

Aaron Ray, Co-Founder & Managing Partner, 5 Horizons Capital

Tuesday, 21 October 2025

12:30 PM - 1:25 PM — COMPANY PRESENTATIONS

Chair: **Rosanne Hyland**, Deputy Chief Executive Officer, AusBiotech

Arovella Therapeutics - Michael Baker, *Chief Executive Officer & Managing Director*
ISOBiotech - Elizabeth Edrich, *Chief Executive Officer*
Neuroscientific Biopharmaceuticals - Nathan Smith, *Chief Executive Officer*
QBiotics Group Ltd - Ebru Davidson, *General Counsel*
Invion - Thian Chew, *Executive Chair & Chief Executive Officer*

Q&A

1:25 PM - 2:15 PM — LUNCH

2:15 PM - 3:10 PM — COMPANY PRESENTATIONS

Chair: **Emma Boscheinen**, Director Communications, AusBiotech

Amplia Therapeutics Ltd - Rhiannon Jones, *Chief Operating Officer*
Filamon - Graham Kelly, *Co-Founder & Chief Executive Officer*
Tiba Biotech - Jas Chahal, *Chief Scientific Officer*
MLS Bio - Penelope Lane, *Chief Executive Officer & Managing Director*

Q&A

3:10 PM - 3:30 PM — **ANALYST UPDATE:** Biotech breakthroughs: ASX market performance and insights

Delve into recent capital raises and IPOs on the ASX, focussing on the healthcare sector. Hear how the ASX Listings Rules - Guidance Notes have been updated to clarify just when a healthcare company should list on ASX.

Chair: **Emma Boscheinen**, Director Communications, AusBiotech

Speaker: **Blair Harrison**, Head Of Listings - New Zealand, ASX

3:30 PM - 4:00 PM — AFTERNOON TEA

4:00 PM - 4:55 PM — COMPANY PRESENTATIONS

Chair: **Hayley van der Meer,** Director Membership Services & Strategic Partnerships, AusBiotech

Immuron Ltd - Steven Lydeamore, Chief Executive Officer
Myopharm Ltd - Karinza Phoenix, *Chief Executive Officer*
Exosome Biosciences - Ishmael Inocencio, *Head of Preclinical Research and Development*
Polyactiva Pty Ltd - Vanessa Waddell, *Chief Strategy Officer*

Q&A

4:55 PM - 5:15 PM — **KEYNOTE:** Punching above our weight

Lessons for Australia from two decades catalyzing Canada's healthcare commercialisation ecosystem of billion $ life science successes

This keynote touches on themes of identifying Best-in-Class healthcare startups, the importance of Connectivity and Syndication, and how Exits occur, contributing to Ecosystem transformation.

Chair: **Rosanne Hyland,** Deputy Chief Executive Officer, AusBiotech

Speaker: **Gerry Brunk**, Managing Director, Lumira Ventures

5:15 PM - 5:20 PM — CLOSING REMARKS

Rosanne Hyland, Deputy Chief Executive Officer, AusBiotech

5:20 PM - 6:30 PM — NETWORKING RECEPTION

Networking accompanied by drinks and canapés in the River Room.

Speaker Spotlight

Emma Boscheinen
Director Communications
AusBiotech

Gerry Brunk
Managing Director
Lumira Ventures

Rebekah Cassidy
Chief Executive Officer
AusBiotech

Medard Fischer
VP Strategic Investments
Cochlear

Rowena Gracey
Director
ARCHIMED

Blair Harrison
Head Of Listings - New Zealand
ASX

Megan Hooton
President
IQVIA Biotech

Rosanne Hyland
Deputy Chief Executive Officer
AusBiotech

Sarah Meibusch
Partner
One-Ventures

Dr. Chris Nave
Founding Partner &
Managing Director
Brandon Capital

The Hon Danny Pearson
Minister for Economic Growth,
Jobs and Minister for Finance
Victorian Government

Aaron Ray
Co-Founder &
Managing Partner
5 Horizons Capital

Kerri Lee Sinclair
Head of Investment
AusBiotech

Hayley van der Meer
Director Membership Services
& Strategic Partnerships,
AusBiotech

Host Industry Body

AusBiotech
Where life science leaders thrive

AusBiotech is Australia's life sciences peak body. For almost 40 years, we have worked to support the growth of our more than 3,000 members as they advance breakthroughs in life science and develop new innovations to help solve some of Australia's and the world's most complex health challenges.

With our unrivalled membership breadth, representing all stages of the health innovation ecosystem, and drawing on our unique national convening power, we advocate for the advancement of Australian life sciences and our members' success as they research, translate, develop and commercialise new health technologies, while supporting knowledge sharing and collaboration to help our life sciences innovators thrive.

Address
Level 33/477 Collins St,
Melbourne VIC 3000

Website
www.ausbiotech.org

Contact
+61 (0)419 394 097

Email
admin@ausbiotech.org

National and Global Reach

AusBiotech has membership in each Australian state, providing a national network to support members and promote the commercialisation of Australian life sciences in both national and international marketplaces. Our initiatives are designed to drive sustainability and growth, offering outreach and access to markets, as well as representation and support for members both nationally and globally.



Host State Partner

Website
www.global.vic.gov.au/scale-in-melbourne

Victoria has one of the largest, most innovative, and globally connected biomedical ecosystems in the world. It is home to a range of globally connected health technology companies and world-leading biomedical integrated precincts and 22 medical research institutes. It offers a cost-competitive environment, access to specialist R&D and manufacturing capabilities, strong collaborative networks and a culture of innovation.

Victoria's expertise in health technologies has been supported by its experienced talent pool, favourable regulatory and R&D environment, world leading infrastructure, private investment and the long track record of the State Government of Victoria's investment into the sector.

Since 2014 the Victorian Government has invested more than $1.3 billion into medical research – making it a leading location for companies taking their innovation to global markets.

The State Government of Victoria has a well-established strategy to help companies become part of the global supply chain in knowledge creation, product development and commercialisation. With a global network of 23 international business offices the Victorian Government is a dedicated partner for Victorian companies going global and international companies developing breakthrough products and treatments entering the Victorian market.

Event Partners

Acuity Capital

Website
acuitycapital.com.au

Contact
1300 180 979

Email
info@acuitycapital.com.au

Acuity Capital is the leading provider of At-the-Market (ATM) funding solutions to ASX-listed companies. We were the first to develop and introduce ATMs into Australia, and since our founding in 2012 we have:

1. Established over 70 ATMs with Australian listed companies, including a number in the life sciences sector
2. Made over $900 million of standby capital available
3. Provided over $160 million in equity capital

ATMs are an integral part of the capital raising landscape in the United States where they have been available to listed companies for more than two decades. In 2024 alone, 486 ATMs were established in the U.S. with a total ATM facility size of over US$135 billion. Of these, 43% were established by companies in the healthcare sector (210 of 486).

What is an ATM?
ATMs offer an additional source of equity capital that is often more efficient and lower cost than traditional capital raising methods. Importantly, ATMs place no restrictions on accessing other forms of capital and can be used as part of a company's capital stack to complement traditional capital raising methods. With an ATM in place, a company can:

1. **Reduce its cost of capital:** ATMs broaden the capital raising options available to a company. They reduce reliance on any one source of capital and help to lower the cost of capital across all sources.
2. **Take advantage of market opportunities:** the ability to quickly activate an ATM allows a company to take advantage of favourable short-term market conditions such as spikes in share price. This is often not possible using traditional capital raising methods.
3. **Maximise capital and reduce dilution:** by giving companies control over the timing, minimum issue price and maximum number of shares to be issued, ATMs help maximise the capital raised while minimising dilution.

ASX

Website
www.asx.com.au

Did you know over 2,000 listed entities from 70+ industries and 40 countries call ASX home. With a combined market capitalisation of $3.1 trillion, companies choosing ASX know they can access capital with confidence.

For more information on an ASX listing, visit our website https://www.asx.com.au/listings.

Event Partners

Citi is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in more than 180 countries and jurisdictions, providing corporations, governments, investors, institutions and individuals with a broad range of financial products and services.

Website
www.citi.com

IQVIA Biotech is a biotech-specialized CRO delivering flexible clinical development solutions for biotech and emerging biopharma companies. Our clinical solutions are built on 25 years of unmatched experience with therapeutically aligned expertise, uniquely designed to deliver full-service solutions on a global scale.

Website
www.iqviabiotech.com

Communications Partner

ir department

Website
www.irdepartment.com.au

IR Department is a leading investor and public relations consultancy, specialising in supporting small and mid-cap ASX-listed and emerging companies to engage effectively with shareholders, investors, analysts, brokers, and the media.

With deep sector expertise and a proven track record, we advise companies across the life sciences, technology, and industrials sectors. Our team partners closely with clients to design and execute investor relations programs, media strategies, and market positioning initiatives that enhance visibility, build stakeholder confidence, and support long-term growth.

Our senior team brings decades of experience in investor relations, media relations, corporate communications, and issues and crisis management. Acting as an extension of our clients' businesses, we provide both strategic counsel and hands-on execution—advising boards and executive teams, while managing day-to-day engagement across capital markets and media.

Clients turn to IR Department for support with capital raisings, transactions, company growth, broader analyst coverage, improved media visibility, and stronger investor and corporate communication. We also help clients shape and articulate their ESG proposition to meet evolving market expectations. Our strategies are always tailored to reflect a company's size, resources, and stage of growth.

Each engagement is insight-led and outcome-driven, combining in-person, digital, and traditional tactics to reach the right audiences. We specialise in translating complex technical and financial information into clear, compelling narratives that resonate with investors, analysts, journalists, and stakeholders—building credibility and laying the foundation for stronger market engagement and reputation.

Media Partner

STOCKHEAD

Website
www.stockhead.com.au

Stockhead is where investors can find the most compelling growth stories from Australia's emerging ASX-listed small caps. We call it the ASX2000 – the innovators and explorers that rarely get a look-in from big media. From biotech breakthroughs to resource discoveries, our journalists and content specialists cover the ideas shaping the future. If you're looking for opportunities beyond the big end of town, this is where you'll find them – free to read and tune in.

Connecting investors with ASX-listed companies

Receive unparalleledaccess toASX-listedcompanies through ASX's programs and initiatives.

ASX CEO Connect

Showcases CEOsand CFOs from large cap companies in a virtual conference six times a year.

ASX SMIDcaps Conference

Hybridconferencehighlighting emerging ASX-listed small to mid-cap companies twice a year.

Equity Research Scheme (ERS)

Supports the production of high-quality, independent research on under-covered, small-cap ASX-listed companies.

Register your interest to be notified about these events.

Scan the QR code

AusBiotech

Invest

Presenting Companies

Amplia Therapeutics Ltd (ASX:ATX)

Dr. Rhiannon Jones
Chief Operating Officer
Amplia Therapeutics Ltd

Address
Level 5, 90 William Street,
Melbourne, VIC, 3000

Website
www.ampliatx.com

Contact
0417 892 488

Email
rhiannon@ampliatx.com

Company Description

Amplia Therapeutics Limited (ASX: ATX) is an Australian, clinical-stage, drug development company focused on the development of potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.

Amplia's pipeline drugs were originally developed by the Cancer Therapeutics CRC (CTx), an Australian industry/academic collaboration that included leading cancer and drug discovery researchers at Australia's top cancer research institutes.

Amplia's Board and Management teams include highly experienced and well-credentialed life-science executives who have extensive international experience in drug development, pharmaceuticals, and life-sciences deal-making.

Pipeline and Developments

Amplia's lead drug narmafotinib (AMP945), is a highly selective and potent inhibitor of FAK and is currently in a Phase 2 clinical trial for pancreatic cancer, with another phase 2 study recently started in Australia and the US, and planning for clinical studies in ovarian cancer well advanced. Narmafotinib has been granted Fast Track Designation and Orphan Drug Designation for pancreatic cancer by the US FDA.

Key Investment Highlights

Pancreatic Cancer
- Global treatment market estimated over US$2.65 billion in 2024 and projected to grow to US$9.57 billion by 2034
- 5 year survival for advanced disease is 3%
- 4,641 estimated diagnoses in Australia in 2024

ACCENT Trial of narmafotinib in Pancreatic Cancer
- Phase 1b/2a study in combination with gemcitabine/Abraxane
- Demonstrated improvement in efficacy over gemcitabine/Abraxane alone (ORR 33% v 23%)
- Drug is well tolerated
- Recruitment complete, trial ongoing

US Pancreatic Cancer Trial
- Narmafotinib in combination with FOLFIRINOX
- IND application cleared by FDA
- Recruitment open in Australia
- Orphan Drug Designation and Fast Track designation granted to narmafotinib in pancreatic cancer in US

Additional Opportunities
- Demonstrated utility in other cancers
- Positive data from pre-clinical studies in multiple tumour types
- IIS in Ovarian Cancer Study in advanced planning stage

Investment Opportunities

Amplia is progressing clinical development for narmafotinib in solid tumours. Top-line data from the current trial in pancreatic cancer has indicated superiority over chemotherapy alone, and mature data is anticipated H1 2026. A trial in the US, also in pancreatic cancer, has commenced, and planning for investigator sponsored studies in other solid tumours is underway. Whilst the pancreatic cancer trials and initial stages of the investigator sponsored studies are part-funded, additional clinical work will require further investment. Investors and collaborators interested in supporting future studies are sought.

Arovella Therapeutics (ASX:ALA)

Dr. Michael Baker
Chief Executive Officer &
Managing Director
Arovella Therapeutics

Address
Level 11/655 Elizabeth Street,
Melbourne, VIC, 3000

Website
www.arovella.com

Contact
0403 468 187

Email
mbaker@arovella.com

Company Description

Arovella Therapeutics is a pre-clinical biotech pioneering a first-in-class, 'off-the-shelf' (allogeneic) iNKT cell therapy platform to treat cancer. The company develops next-generation therapies for both haematological malignancies and solid tumours. Its lead asset, ALA-101, is a CAR-iNKT therapy targeting the validated CD19 antigen for B-cell lymphomas and leukemias.

Arovella is expanding into high-unmet-need solid tumours by targeting Claudin 18.2, a validated antigen in gastric and pancreatic cancers. Its solid tumour programs will incorporate IL-12-TM cytokine 'armouring' technology to enhance potency by overcoming the immunosuppressive tumour microenvironment, aiming to deliver therapies with superior efficacy, safety, and patient access.

Pipeline and Developments

Arovella has achieved significant de-risking milestones and is advancing a diversified pipeline toward key clinical catalysts. The company has established a clinic-ready manufacturing process for ALA-101, based upon its patent-protected manufacturing process to generate CAR-iNKT cells. Arovella's first-in-human Phase 1 trial for ALA-101 is anticipated to commence in early 2026, representing a major near-term value inflection point.

The solid tumour pipeline is expanding through strategic collaborations, including a preclinical CLDN18.2-CAR program with world-renowned CAR-iNKT expert Professor Gianpietro Dotti at University of North Carolina. Arovella continues to evaluate for in-licence novel Chimeric Antigen Receptors (CARs) to target a range of different cancer types.

Key Investment Highlights

The investment thesis for Arovella is underscored by a scientifically differentiated cell therapy platform. Arovella's iNKT cells offer a multi-modal mechanism of action, combining direct CAR-mediated killing, recruitment of the host immune system, and elimination of tumour-supportive cells, providing a key advantage over conventional CAR-T therapies, especially in solid tumours. This novel biology is paired with a de-risked approach that utilises clinically validated cancer targets (CD19 and CLDN18.2) and leverages the known favourable safety profile of iNKT cells.

The platform's modular, 'plug-and-play' architecture is expected to enable capital-efficient expansion into new indications. This scientific and strategic foundation is overseen by an experienced management team and Board with deep domain expertise in successfully advancing cell therapies from lab to clinic.

Investment Opportunities

Arovella presents a compelling opportunity to invest in a leader in the next generation of allogeneic cell therapies. The 'off-the-shelf' model directly addresses the significant logistical, cost, and manufacturing challenges of autologous CAR-T, positioning Arovella for a more scalable and commercially viable future.

The company is one of only a handful of developers in the CAR-iNKT space and is poised to be a leader with its expected near-term commencement of a first-in-human clinical trial for ALA-101. Successful development of technologies to address high unmet solid tumours creates substantial upside potential. This opportunity is secured by a robust IP portfolio around its manufacturing process, and additional CARs and armouring strategies.

Avecho Biotechnology (ASX:AVE)

Dr. Paul Gavin
Chief Executive Officer
Avecho Biotechnology

Address
Unit A8, 2A Westall Road,
Clayton, VIC, 3168

Website
www.avecho.com.au

Contact
0417 246 449

Email
pgavin@avecho.com.au

Company Description

Avecho is a clinical-stage Biotechnology company with a novel drug delivery technology called TPM. TPM is used to increase drug solubility and/or absorption to develop dosage forms with better performance and commercial differentiation.

Avecho's lead asset is a proprietary oral cannabidiol (CBD) capsule with increased absorption for greater therapeutic effect. It is targeting over-the-counter registration with the TGA in Australia, followed by rest-of-world (FDA, EMA).

Pipeline and Developments

Avecho's lead asset is a proprietary CBD TPM® soft-gel capsule for treating insomnia, a condition affecting up to 30% of the global population and representing a market worth over US$5.2 billion.

The company is conducting a pivotal Phase III, multi-centre, randomized, double-blind, placebo-controlled trial designed to meet TGA, FDA, and EMA regulatory standards, with a key interim analysis expected in early 2026.

A successful trial would support TGA registration, making it the first registered pharmaceutical CBD treatment for insomnia. Uniquely, the TGA allows registered oral CBD products to be sold over-the-counter, offering a significant commercial advantage over prescription medicines.

In March, Avecho licensed Australian rights to Sandoz AG, a key validation milestone that has triggered further global licensing interest from additional parties.

Key Investment Highlights

Avecho's proprietary CBD capsule is designed to capitalise on a unique Australian regulatory opportunity. In response to concerns over the unregulated medicinal cannabis market, the TGA allowed pharmaceutical CBD products to be registered as over-the-counter (OTC) medicines. This means they can be sold directly through pharmacies without a prescription—offering a major commercial advantage over traditional prescription drugs. While Australia is not typically a primary market of interest for pharmaceutical registration, this pathway presents a rare opportunity, which played a key role in Sandoz AG's decision to license the product. With 9.5 million Australians reporting sleep-related issues, the market potential for an effective OTC CBD treatment is significant and highly attractive.

Investment Opportunities

Avecho offers a compelling investment opportunity as it advances a proprietary CBD capsule for insomnia through a pivotal Phase III clinical trial. A successful trial will support registration with Australia's Therapeutic Goods Administration (TGA), positioning the product to become only the second registered pharmaceutical CBD medicine globally—unlocking significant commercial potential.

Key Highlights:

- The Phase III trial is in its final stages of recruitment ahead of a planned interim analysis in early 2026.
- Interim analysis will be a major inflection point, providing the first indication of efficacy.
- A positive interim result will accelerate the path toward trial completion and TGA submission.
- The program has received strong commercial validation through a licensing deal with Sandoz AG for Australian rights.
- Avecho is now in discussions with additional partners for rights in high-value international markets.
- Near-term data and expanding licensing opportunities make this a high-potential biotech investment.

BiomeBank (ASX:BIO)

A/Prof. Samuel Costello
Chief Executive Officer &
Co-Founder
BiomeBank

Address
Level 3, 21-24 North Terrace,
Adelaide, SA, 5000

Website
www.biomebank.com

Contact
0413 311 793

Email
scostello@biomebank.com

Company Description

BiomeBank is a leading microbiome therapeutics company with a mission to restore human gut microbial ecology.

BIOMICTRA,TM is the first approved donor derived microbiome therapy in the world (approved by TGA in Australia for C.difficile infection). We have leveraged BIOMICTRA to develop our CONSORTIOMETM platform for cultured microbiome therapies.

The CONSORTIOME platform allows large scale production of disease targeted microbiome therapies with the diversity and emergent function of a healthy human microbiome. Products that capture the breadth of function present in donor derived products but with controlled composition and scalable, low-cost production.

Our first such therapy, BB265, is designed to treat ulcerative colitis and contains 103 of the most prevalent bacterial species in the human bowel into one drug substance. It contains >93% of the known gene families in a healthy human gut microbiome. BB265 will enter a phase 1b human study in 2026.

Pipeline and Developments

BiomeBank has a growing pipeline of microbiome-based therapies at different stages of development. Biomictra® is approved in Australia for the treatment of recurrent C. difficile infection, giving patients access to the first donor-derived microbiome therapy worldwide. The company's pipeline also includes two next-generation Live Biotherapeutic Products: BB265, schedule to enter a Phase 1b study for ulcerative colitis in 2026, and BB128, in development for an orphan disease indication, primary sclerosing cholangitis. In addition, BiomeBank is in discussions with probiotic companies regarding co-development of products for the international probiotic markets. The company's pipeline is supported by its culture collection and manufacturing platform, helping new discoveries move into the clinic quickly and reliably.

Key Investment Highlights

BiomeBank has delivered a series of world-first achievements and built a strong foundation for growth. This foundation includes:

- The first-ever regulatory approval of a donor-derived microbiome therapy (Biomictra®) generating revenue and drug discovery data from clinical trials
- The world's most diverse culture collection of microbes from screened human donor
- Microbiome drug discovery platform with unprecedented, unique and defensible ability to co-culture the most prevalent bacteria in a healthy human microbiome, containing over 90% of know gene families in a healthy human microbiome
- Diversified portfolio and risk by leveraging platform for development of both live bacterial therapeutics (pharmaceuticals) and consumer health focused probiotics
- Highly differentiated microbiome therapy for ulcerative colitis (BB265) entering phase 1b human trial in 2025

Investment Opportunities

BiomeBank is currently raising $20 million, alongside a strategic investor, to fund the next stage of growth. This raise will support the Phase 1b clinical trial of BB265 in ulcerative colitis, further development of the company's Live Biotherapeutic Product pipeline and co-development of two probiotics with the strategic partner. Funds will also strengthen manufacturing scale-up and extend BiomeBank's reach into international markets. With an approved product already on the market, a robust pipeline, and the infrastructure to manufacture GMP approved products, BiomeBank offers investors a unique opportunity to back a clinically validated, globally scalable platform. BiomeBank is building the future of microbial medicine with world leading technology, a clear regulatory path and internal manufacturing capability to meet multiple near term value infection milestones.

BlinkLab Ltd (ASX:BB1)

Brian Leedman
Chairman
BlinkLab Ltd

Address
L4 216 St George's Tce, Perth, WA, 6000

Website
www.blinklab.org

Contact
0412 281 780

Email
brian@blinklab.org

Company Description

BlinkLab Limited, a company founded by neuroscientists at Princeton University, over the past several years has fully developed a smartphone based diagnostic platform for autism and ADHD. Our most advanced product is an autism diagnostic test that leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention.

BlinkLab is led by an experienced management team and directors with a proven track record in building companies and vast knowledge in digital healthcare, computer vision, AI and machine learning. Our Scientific Advisory Board consists of leading experts in the field of autism and brain development allowing us to bridge most advanced technological innovations with groundbreaking scientific research.

Pipeline and Developments

- Q3 2025 - Results from Initial 200 patients FDA study in autism.
- Q2 2026 - Results from 1,000 patients FDA study in autism.
- Q3 2026 - Results from 1,000 patients study CE Mark study in ADHD.
- Q3 2026 - Outcome from FDA 510(k) submission.

Key Investment Highlights

BlinkLab is a leading digital healthcare company focused on AI-powered diagnostics engaged in multiple clinical studies in the US, Europe and Australia for the early diagnosis of autism and ADHD in young children using only a smartphone.

Having listed on the ASX in April 2024, the company has raised capital at a significant premium to its IPO that introduced the first fund managers onto its register. Significant milestones concerning both an FDA regulatory study in autism and a European study in ADHD are due to read out in the next twelve months.

Investment Opportunities

Unique digital healthcare company using AI and smartphone technology to diagnose neurological illness in young children. Initially focused on autism and ADHD, early diagnosis results in better outcomes for the child and his/her family and the general healthcare system through the provision of an accurate screening test prior to the commencement of lengthy and costly formal medical diagnosis.

BlinkLab has partnered with leading medical university hospitals in the US, Europe and Australia to conduct regulatory clinical studies prior to planned commercialisation rollout in 2027.

Chimeric Therapeutics (ASX:CHM)

Dr. Rebecca McQualter
Chief Executive Officer
Chimeric Therapeutics

Address
62 Lygon Street, Carlton,
VIC, 3053

Website
www.chimerictherapeutics.com

Contact
0451 896 420

Email
rmcqualter@chimerictherapeutics.com

Company Description

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

Pipeline and Developments

- Our world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of todays most innovative solutions, and has shown a consistent ability to deliver on its objectives.
- Chimeric's diversified portfolio includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies, with assets being developed across multiple different disease areas in oncology with 3 clinical stage programs.
- We currently have 4 clinical trials running in humans.

Key Investment Highlights

Our Lead program CHM CDH17 a cell therapy targeting bowel cancer and GI cancers has upcoming data read outs; our CHM CORE-NK also has phase 1 data in the coming months.

Investment Opportunities

CHM is looking for investors to push these programs into phase 2.

Exosome BioSciences

Dr. Ishmael Inocencio
Head Of Preclinical Research and Development
Exosome BioSciences

Address
27-31 Wright St, Clayton, VIC, 3168

Contact
0422 106 584

Email
ishmael.inocencio@monash.edu

Company Description

Exosome BioSciences (EBS) is a clinical stage biotech start-up from the Hudson Institute of Medical Research, Monash Health, and Monash University, backed by world-leading researchers with over 20 years of expertise. We harness the power of specific exosomes—cellular messengers with potent anti-inflammatory and regenerative properties.

Our team has developed a novel therapy for a range of inflammatory and fibrotic diseases. Through robust preclinical validation and established methods of manufacture, EBS is developing a safe, scalable, and effective exosome therapy that offers a potential lasting solution for numerous diseases worldwide

Pipeline and Developments

EBS has developed a, "bench to bedside" pipeline for its patented exosome-based therapy. Key advancements include a primary cell bank and GMP-compliant purification methods, enabling scalable, clinical-grade manufacturing for primary-derived exosomes.

Our preclinical pipeline features robust in-vitro assays and validation in animal models to confirm the mechanism of action, safety, and bioactivity. Early proof-of-concept studies demonstrate significant therapeutic impact across various diseases, including liver, gastrointestinal, and pulmonary conditions, leading to the successful translation of these findings into proof-of-concept Phase 1 clinical studies. Moving forwards, we intend on further developing our pipeline to use exosomes derived from an immortalized, stable master cell bank as our clinical candidate. Immortalized candidates provide significantly greater consistency compared to primary cells.

Key Investment Highlights

Exosome BioSciences (EBS) leverages a cell-free exosome therapy with significant advantages in safety, scalability, and regulatory compliance over traditional cell therapies. The company's proprietary, GMP-compliant manufacturing process and Proof-of-concept asset shows compelling preclinical and clinical data across multiple high-value indications. Backed by an experienced leadership team and a robust IP portfolio, EBS has significantly reduced its development risk, enhancing the likelihood of successful clinical translation.

These achievements position EBS at the forefront of exosome therapeutics, a rapidly growing regenerative medicine sector projected to reach nearly $3.7 billion by 2030. EBS represents an attractive opportunity for investors seeking next-generation biologics and platform technologies with broad commercial applicability.

Investment Opportunities

Exosome BioSciences (EBS) offers a compelling investment opportunity into a clinical stage start-up. EBS is seeking strategic capital to accelerate the clinical translation of its exosome platform and expand its GMP manufacturing infrastructure. Near-term investment will support the development of exosomes derived from immortalized master cells, finalising IND-enabling studies, scaling production, and progressing its future lead immortalized candidate into a Phase I Bridging Study, while also advancing other preclinical programs toward human trials.

EBS's platform provides a therapy for multiple indications, creating significant out-licensing opportunities and strategic partnerships with pharmaceutical companies. Investors gain exposure to a high-value market with significant barriers to entry, strong IP protection, and potential for early value inflection points through partnering or out-licensing deals. With clear clinical pathways and a scalable pipeline, EBS is positioned to deliver significant return on investment and long-term growth.

Filamon

Dr. Graham Kelly
Chief Executive Officer
& Co-Founder
Filamon

Address
Suite 201, 697 Burke Rd,
Camberwell, VIC, 3124

Website
www.filamon.com

Contact
0499 326 215

Email
corporate@filamon.com

Company Description

Filamon is a public, unlisted company currently focused on developing improved treatments for chronic inflammatory diseases including cancer and ophthalmic and neurodegenerative diseases.
The Filamon rationale is that chronic age-related conditions typically involve multiple pro-inflammatory genes that require a new generation of drugs with multi-function capabilities.

Pipeline and Developments

Filamon is building a pipeline of drugs, based on three proprietary technology platforms to target the key drivers of chronic, age-related diseases.

1. **ALPHA platform:** cyclic peptides modulating protein-protein interactions that underpin chronic inflammatory disease processes.
- Kesonotide is a clinical-stage drug designed to block cancer cell-generated inflammation. Kesonotide is soon to be trialled in a Phase Ib/IIa clinical study in patients with late-stage solid cancers
- ALPHA-D1 is an analogue of kesonotide modified to degrade EGFR. This new class of anti-cancer drug known as LYTAP (Lysosome Targeting Peptides) is designed to be mutant-agnostic and overcome the instability of the EGFR gene
- ALPHA-D3 is designed to eliminate the formation of toxic protein oligomers in the brain in neurodegenerative disease, including dementias.

2. **BETA platform:** small molecule drugs, selective inhibitors of MAPK signalling.
- BETA-TT8 is being developed as a self-administered treatment of macular degeneration
- BETA-TT17 is being developed as an oral immunotherapeutic reversing T cell exhaustion in solid cancers.

3. **SIGMA platform:** small molecules aimed at targeting proteins with prion behaviour. This platform is still in the drug discovery phase.

Each platform is supported by a strong Intellectual Property (IP) portfolio.

Key Investment Highlights

Filamon has concluded its Stage 1 growth plan funded by private investment and government grants. This initial phase has led to five drug candidates currently in various stages of development including a clinical-stage drug candidate.

Investment Opportunities

The increasing ageing of the global community has created an urgent need for drugs appropriate for complex diseases. Meeting the needs of this burgeoning ageing population requires a new approach. Filamon seeks to be an important part of this new approach.

GoLiver Australia Pty

Dr. Sami Bou-antoun
Chief Executive Officer
GoLiver Australia Pty

Address
40 City Road Southbank - Level 17 HWT Tower, Melbourne, VIC, 3006

Contact
+33 608 022 381

Email
SamiBouAntoun@golivertx.com

Company Description

GoLiver is a clinical-stage, innovative biotech and a changemaker in the liver cell therapy field.

The company set a new paradigm in cell therapy: Healing the liver from within, powered by cells that deliver a "secretome" before disappearing, leaving only regeneration behind! This groundbreaking work has been recognized and supported by the French government, positioning Goliver to become the first liver biotherapy company in Europe.

As part of a global expansion strategy, Goliver is establishing a scientific hub in Melbourne. Aiming to bring the first liver biotherapy to market by 2030, Goliver is currently raising A$25 million to accelerate the next steps. This includes GMP production of cell batches (in Brisbane) and launching Australian clinical trials by end-2026 (in Melbourne).

Pipeline and Developments

Family of patents covering the cells and production platform

- GStemHepTM cells : A line of hepatic stem cells representing a Novel Therapeutic concept
- iMilleniumTM Platform : A Highly scalable production platform limiting the cost of cell production
- GTLX-001 product : ready-to-use product for bedside application

The technology covers other applications in lung, heart and kidney regeneration as in Plasma production.

Key Investment Highlights

The need for next phase is 25 million Australian dollars
The use of the money:

- Recruiting the Australian team
- Tech transfer to CDMO in Australia
- Development of the Master Cell Bank
- Production of the clinical GMP batches
- First-in-human (Phase I-IIa) clinical trial

Investment Opportunities

- First mover in that field.
- Huge Roi for investors.
- Valuation of the company within 5 years: more than one billion US dollars
- Very Quick access to the market with the first application as an alternative to Liver transplant.
- Maximized success rate of clinical trials forecasted: 90% vs 10% current rate.
- Clinical phase cost is very low compared to what Pharma companies usually spend.
- Universal Drug Cell for all patients.
- Versatile technology: we will also address chronic Liver conditions as of 2027.
- The current hepatic disease treatment market is evaluated around $30 billion.
- With Goliver's technology there is an opening of another additional $30 billion segment over the next 10 years.
- Our production technology does not require any unusual industrial equipment.
- The production cost of each cell batch is 20 fold less than the current costs of all existing solutions.
- Short time needed to assess the clinical Proof of Concept.
- Orphan drug status.

Haemalogix Ltd

Alan Liddle
Executive Director
Haemalogix Ltd

Address
Suite 306, Level 3, 343 George St, Sydney, NSW, 2000

Website
www.haemalogix.com

Contact
0414 991 770

Email
alan@haemalogix.com

Company Description

HaemaLogiX is a clinical-stage Australian biotechnology company developing next-generation immunotherapies for blood cancers, with a key focus on multiple myeloma. The company's pipeline includes assets in two major drug classes: monoclonal antibodies and CAR T cell therapies.

Its lead immunotherapy, KappaMab, has shown compelling results through completed Phase 2b trials, demonstrating potential to enhance the current standard-of-care. A key competitive advantage is that HaemaLogiX's therapies target cancer cells while sparing normal plasma cells, enabling a normal immune response. These assets target the largest segments of the $23 billion multiple myeloma market.

Pipeline and Developments

A key differentiator, HaemaLogiX is targeting two new cancer targets, KMA and LMA. The immunotherapies attach to these targets and trigger an immune response, which destroys the myeloma cells. Multiple myeloma patients will either be KMA (~70% of patients) or LMA (~30% of patients) positive in their diagnosis, making the ability to uniquely address these targets a critical new tool.

HaemaLogiX's two lead products target KMA:

1. KappaMab: a monoclonal antibody has completed Phase 1, 2a and 2b trials and is entering a Phase 2b dose escalation trial
2. KMA.CAR-T cell: a CAR T cell therapy - HaemaLogiX's first (Phase 1) human clinical trial for KMA.CAR-T cell will be conducted in collaboration with Peter Mac

Outside of the two lead assets, HaemaLogiX intends to advance a pipeline of next-generation immunotherapies designed to target KMA and LMA on cancerous plasma cells associated with blood cancers like multiple myeloma and AL amyloidosis.

Key Investment Highlights

Key investment highlights:

- HaemaLogiX is developing highly effective drugs for the US$23.3 billion myeloma market - a disease which is currently incurable
- The lead assets target abnormal plasma cells, while preserving immune response. This enables the patient's immune response to fight infections, enhancing patients' health and maintaining their quality of life.
- Proven track record – in the most recent Phase 2b study, KappaMab achieved 46% reduction in risk of death 83% vs 45% overall response rate
- Clear pathway for validation and value creation
- Supported by robust IP (80 patent filings across nine strategic patent families), orphan drug designation, and specialist investor backing
- Deeply experienced Board and Management team

Investment Opportunities

Currently an unlisted public company, HaemaLogiX is grateful to have a strong support base of investors, including specialist healthcare investors.

As we move toward the next Phase 2b clinical trial for KappaMab, we welcome interest from investors interested in supporting the company's next stage of growth.

Humble Bee Bio Pty

Bridgit Hawkins
Chief Executive Officer
Humble Bee Bio Pty

Address
Level 2, 57 Willis St, Wellington, 6011, NZ

Website
www.humblebee.co.nz

Contact
+64 274 119 336

Email
bridgit@humblebee.co.nz

Company Description

Humble Bee Bio presents a transformative opportunity in the rapidly growing anti-aging market through HBB02, a breakthrough molecule derived from patented bee genome sequences that increases elastin production by over 500% compared to existing alternatives. The ability of HBB02 to reactivate and guide the body's native elastic fibre development pathway represents a significant breakthrough for the anti-aging cosmetics market, addressing a major demand for efficient and innovative ingredients.

The platform pipeline is backed by strong data on safety, stability and manufacturability.
Elastin is a key ingredient not only in skin but many parts of the body, including repair from traumatic wounds, burns and in the pulmonary and cardiovascular systems.

The compelling results from trials of HBB02 alongside a growing market for anti-aging treatments and longevity therapies position Humble Bee Bio for strong and sustained growth.

Pipeline and Developments

The key milestones for 2025 are:

- Complete first-in-human proof of concept study with two delivery methods
- Commence clinical efficacy study
- First Joint Development Agreement in negotiation

2026 Objectives

- Secure 1-2 early license deals
- Launch MVP in test market
- Expand clinical validation data

Key Investment Highlights

Why Now? There is a massive unmet need in the elastin restoration market. "Notox" and "Natural" trends are creating demand for non-invasive alternatives, adding to the current demand for products that provide a visible difference for consumers.

- Clear technical validation
- Strong early market validation and interest in the lead molecule
- Established regulatory pathways for cosmetic applications lead to early revenues
- Strong IP portfolio

There are clear exit opportunities

- Strategic acquisition by major cosmetics company
- Licensing portfolio generating significant recurring revenue
- Series A growth funding for expanded applications including medical.

Investment Opportunities

Currently raising a $4 Million NZD equity round.

Immuron Ltd (ASX:IMC)

Steven Lydeamore
Chief Executive Officer
Immuron Ltd

Address
Building 10, 25-37 Chapman Street, Blackburn North, VIC, 3130

Website
www.immuron.com.au

Contact
0438 027 172

Email
steve@immuron.com

Company Description

Immuron Limited (ASX:IMC | NASDAQ:IMRN) is a dual-listed Australian biopharmaceutical company transforming how infectious diseases are prevented and treated. Using a proprietary oral antibody platform, Immuron delivers clinically backed therapies that act directly in the gut — including Travelan®, a market-leading product targeting travellers' diarrhea. With global commercial traction, a differentiated technology base, and a pipeline addressing high-impact health challenges, Immuron is advancing a new frontier in accessible, gut-targeted health solutions.

Pipeline and Developments

Three commercial products: Travelan® (traveller's diarrhoea); Protectyn®, and ProIBS (irritable bowel syndrome).

Three clinical programs: Travelan®: IMC: Phase 2 CHIM trial (n=60), Travelan®: USU: Field Study (n=851), IMM-529 (CDI): IMC: IND for Phase 2 trial (n=60).

One preclinical program: IMM-986 (vancomycin-resistant enterococci)

Status:

- Travelan®: IMC: Phase 2 CHIM trial (n=60). Complete; waiting on USU study results before requesting end of Phase 2 meeting with FDA
- Travelan®: USU: Field Study (n=851). Complete; topline data anticipated in October 2025
- IMM-529 (Clostridioides difficile infection): IMC: IND for Phase 2 trial (n=60)IND submission complete
- IMM-986 (vancomycin-resistant enterococci). Initial pre-clinical research studies anticipated to be completed by year-end 2025

Key Investment Highlights

Global Biotech with Real-World Impact
Immuron is one of few ASX-listed biopharma companies with both commercialised products and a U.S. dual listing. With a global footprint spanning Australia, the U.S., and Canada, the company is executing a cross-border growth strategy.

Strong Commercial Momentum, Billion-Dollar Market
As global travel rebounds and gut health gains consumer traction, Immuron is well-positioned in a market exceeding US$1B. New channel growth, geographic expansion, and Phase 3 readiness support compelling upside potential.

First-Mover in Oral Polyclonal Antibody Therapy
Immuron's platform uses hyperimmune bovine colostrum to deliver targeted antibodies orally with broad potential across infectious and inflammatory diseases. This differentiated modality has been validated in clinical and military settings, and underpins a pipeline designed for scale and speed.

De-risked Biotech with Upside
Unlike many early-stage biotechs, Immuron combines validated technology, commercial revenue, and regulatory progress - creating a unique blend of short-term traction and long-term value creation.

Investment Opportunities

Immuron is seeking:

- access to investors to share the Immuron story, to inspire buying on market and interest in future capital raises.
- partners to expand geographical sales of Travelan® (traveller's diarrhoea).
- investment/development/marketing partners for IMM-529 (clostridioides difficile infection).

Invion (ASX:IVX)

A/Prof. Thian Chew
Executive Chair &
Chief Executive Officer
Invion

Address
Level 11 385 Bourke Street,
Melbourne, VIC, 3000

Website
www.inviongroup.com

Contact
+852 5129 8800

Email
thian.chew@inviongroup.com

Company Description

Invion (ASX: IVX) is a clinical-stage company developing a platform technology, called Photosoft™, for the treatment of a range of cancers and infectious diseases.

Photosoft is the next-generation Photodynamic Therapy (PDT) and Invion recently secured U.S. FDA Orphan Drug Designation for its lead cancer drug candidate, INV043, for the treatment of anal cancer.

It also released encouraging early data for its ongoing Phase I/II non-melanoma skin cancer (NMSC) trial and positive final results from an investigator-led Phase II prostate cancer trial.

Preclinical results showed Photosoft completely regressed a range of cancers, such as triple negative breast and ovarian cancers and stimulated the body's immune system to continue fighting the cancer.

Invion has developed a portfolio of patent protected compounds. INV043 also has the potential to work as a theragnostic (therapy and a diagnostic) tool. Red light activates the photosensitive drug while violet light causes cancers to fluoresce.

Pipeline and Developments

Initial results from the first patients in the Phase I/II NMSC trial didn't find any adverse events or pain and recorded an observable reduction in the NMSC lesion size.

Meanwhile, results from the Phase II prostate cancer trial showed a 40-44% positive response rate. The treatment only had mild side effects and was well tolerated after six rounds of the treatment.

These results support Invion's preclinical findings. In vivo studies showed INV043 is safe, non-scarring and non-toxic and only accumulates in cancer cells and not healthy tissue.

Invion will undertake an anogenital cancer clinical study, which will build on the preclinical work done at Peter Mac that found combining INV043 with immune checkpoint inhibitors (ICIs) substantially increased the response rate, resulting in 80% tumour free subjects vs 12% in the standalone ICI group.

Separately, Invion partnered with pharma groups Hanlim Pharm and Dr. inB where. These partners will fund and undertake studies using Photosoft to treat GBM, oesophageal cancer and HPV.

Key Investment Highlights

Invion has multiple inflection points following the release of encouraging human data from two distinct cancer types and its pre-clinical successes.

- It has more than one opportunity to commercialise its platform technology as it has developed over 300 unique and patented photosensitiser compounds.
- The technology is shown to be safe and highly tolerated in humans.
- NV043 has shown to regress multiple types of cancers and has the potential to stimulate the immune system and impede/control the spread of cancers.
- INV043 has theragnostic potential.
- In vivo studies showed that INV043 can also to be used in combination therapies. This may present opportunities for Invion to partner with global pharmaceutical groups.
- Other compounds in the Photosoft portfolio have been found to be effective against a wide range of viruses, bacteria and fungi.
- The diversity helps to materially de-risk Invion's development strategy and the technology is leveraged to multiple large and attractive markets.

Investment Opportunities

Invion has several key milestones over the next 1-2 years. We anticipate further results from our Phase I/II skin cancer trial and the commencement of a new anogenital cancer study.

We also expect results from partner-funded GBM and HPV studies and are actively identifying new cancer and infectious disease indications for clinical trials.

While several of our programs are largely partner-funded, providing Invion a balance sheet advantage, a further capital contribution will accelerate our development plans.

This will enable us to leverage the multiple commercialisation opportunities for Photosoft. Invion remains open to strategic partnerships to advance our platform technology.

ISOBiotech

Dr. Elizabeth Edrich
Chief Executive Officer
ISOBiotech

Address
Suite 6/81 Brisbane Street,
Ipswich, Brisbane, QLD, 4000

Website
www.isobiotech.com.au

Contact
0481 232 178

Email
elizabeth@isobiotech.com.au

Company Description

ISOBiotech is a rapidly emerging Australian start-up revolutionising the field of molecular diagnostics. Backed by nearly two decades of expertise, they have developed a proprietary isothermal amplification technology - **Isothermal PCR Amplification (IPA™)** - that delivers rapid, accurate, and scalable detection of any known infectious disease.

At the core of their innovation is **IPA™**, a novel amplification chemistry that pairs seamlessly with their compact, easy-to-use diagnostic platform, the **RapidDetector™**. Together, they enable fast, reliable, and decentralised testing, without the need for complex instrumentation or laboratory infrastructure.

ISOBiotech's In Vitro Diagnostic (IVD) intended solutions, certified to ISO13485:2016 standards, can transform the way infectious diseases are detected, monitored and managed, by empowering clinicians and public health systems with tools that are accurate, affordable, and accessible. Their technology is well-suited to meet global demands for point-of-care diagnostics, especially in resource-limited settings or during health emergencies such as epidemics and pandemics.

Pipeline and Developments

ISOBiotech is redefining rapid molecular diagnostics through innovation. Their mission is to accelerate the development of simple but affordable cutting-edge in vitro diagnostic solutions that empower clinicians with faster, more accurate, and accessible tools for disease detection and monitoring. ISOBiotech has used IPA™ to develop a robust pipeline of over 30 different IVD assays targeting high impact infectious diseases including AMR, and partnered with research institutions, hospitals and other biotech firms to streamline regulatory pathways and scale commercialisation. ISOBiotech's proprietary platform is adaptable across multiple sample types and disease conditions, andits R&D framework is very agile with rapid prototyping and validation cycles. Importantly, ISOBiotech is committed to bringing diagnostics to underserved markets. **The vision is to become a strategic leader in using rapid molecular platforms to transform patient outcomes through early detection.**

Key Investment Highlights

The global molecular diagnostics market is forecast to exceed $40B by 2030 because of rising infectious disease threats and a quest for decentralised healthcare. ISOBiotech's proprietary RapidDetector™ platform provides 20-minute results, is comparable with lab-based PCR and is adaptable across multiple sample types and disease targets, meaning ISOBiotech has unprecedented potential in detecting and monitoring any infectious disease. Their RapidDetector™, a compact and portable device, is ideal for consultation rooms, pharmacies and remote care, especially in resource-limited settings. With recuring revenue through consumables like IPA™ reagents and licensing, ISObiotech's scalable business model is centred around B2B channels with hospitals, diagnostic/pathology labs, and NGO/government health programs, including future plans to get into consumer health and at-home testing markets. ISOBiotech has a strong proprietary IP portfolio that covers its IPA™ chemistry, RapidDetector™ design, and output algorithms, with ISO13485:2016 certification providing early engagement with regulatory bodies for accelerated approval pathways and global deployment.

Investment Opportunities

ISOBiotech is positioned to transform the future of healthcare with its RapidDetector™ platform, delivering lab-grade results at the point-of-care. The rising global demand for rapid, decentralised testing post-pandemic, early intervention, and pathways to regulatory approval are among the huge opportunities for growth. ISOBiotech's core differentiators include proprietary technology, PCR-comparable sensitivity and specificity, and portable, scalable devices suitable for clinics, pharmacies, and remote settings. Strategic partnerships are available with academics, hospitals/diagnostic labs and biotech firms, including a clear path to revenue through B2B healthcare networks and government contracts. ISOBiotech's high growth potential includes respiratory infections, STIs, AMR and oncology. As the global IVD market is projected to exceed $40B by 2030, demand is surging towards rapid, accurate and decentralised testing in infectious diseases, oncology and genetic screening.

ISOBiotech is currently valued at 3,000,000 – 10,000,000 AUD for pre-clinical diagnostic startups in Australia. Imagine its valuation in clinical diagnostics with your help?

MLS Bio

Penelope Lane
Chief Executive Officer &
Managing Director
MLS Bio

Address
344 City Road, South Bank,
VIC, 3006

Website
www.isobiotech.com.au

Contact
0408 016 016

Email
penelope@mlsbio.com

Company Description

MLS Bio is advancing a multi-asset pipeline anchored by MLS-269, its oncology lead candidate in prostate cancer. Preclinical results demonstrate strong potential to overcome resistance mechanisms, improve tolerability, and expand therapeutic options in advanced and metastatic disease. Within its pipeline, the company is developing MLS-289, a broad-spectrum antiviral with applications across human and animal health, including Porcine Reproductive and Respiratory Syndrome (PRRS). Together, these assets represent a differentiated approach: oncology programs designed to redefine standards of care, and antiviral programs addressing global infectious disease challenges. MLS Bio is progressing IND-enabling studies and preparing to initiate clinical development, supported by strategic collaborations with leading academic and clinical research institutions. The company's pipeline reflects its core strategy — translating breakthrough science into scalable therapies that target urgent unmet needs across oncology and infectious disease.

Pipeline and Developments

MLS Bio offers investors a unique opportunity to participate in a first-in-class oncology program with broad potential impact. Prostate cancer represents a multi-billion-dollar market, yet existing therapies face persistent challenges in resistance, tolerability, and advanced disease management. MLS-269 is designed to directly address these limitations, positioning it as a highly differentiated asset with significant clinical and commercial upside. The company is led by an experienced executive team with a proven record of scaling biotech ventures and securing global partnerships. MLS Bio has already attracted angel and government support and is preparing for its next financing stage to accelerate clinical development. Its opportunities in oncology and additional platform assets in antivirals, the pipeline provides risk diversification while maintaining a strong path toward value inflection. For investors, MLS Bio represents a compelling blend of innovative science, high-growth markets, and clear translational potential.

Key Investment Highlights

MLS Bio is currently advancing a structured capital pathway designed to accelerate MLS-269 into clinical development for prostate cancer. Following the successful close of an oversubscribed Angel SAFE note (A$1M), the company has opened a US$5M SAFE Note round with a 30% discount on Series A equity conversion and a minimum investment of US$500,000. This instrument bridges to MLS Bio's upcoming US$20–25M Series A round, which is being led by a U.S.-based institutional investor already in due diligence.

Proceeds from the SAFE round will fund toxicology execution for oncology programs, IND-enabling studies, and expansion of clinical and commercial infrastructure. Investors committing US$1M+ also retain rights to follow-on at Series A under the same 30% discount. With MLS-269 in prostate cancer and MLS-289 in antivirals, MLS Bio presents a compelling opportunity: early entry at significant valuation, leverage into a biotech positioned for global clinical impact, and near-term value inflection.

Investment Opportunities

ISOBiotech is positioned to transform the future of healthcare with its RapidDetector™ platform, delivering lab-grade results at the point-of-care. The rising global demand for rapid, decentralised testing post-pandemic, early intervention, and pathways to regulatory approval are among the huge opportunities for growth. ISOBiotech's core differentiators include proprietary technology, PCR-comparable sensitivity and specificity, and portable, scalable devices suitable for clinics, pharmacies, and remote settings. Strategic partnerships are available with academics, hospitals/diagnostic labs and biotech firms, including a clear path to revenue through B2B healthcare networks and government contracts. ISOBiotech's high growth potential includes respiratory infections, STIs, AMR and oncology. As the global IVD market is projected to exceed $40B by 2030, demand is surging towards rapid, accurate and decentralised testing in infectious diseases, oncology and genetic screening.

ISOBiotech is currently valued at 3,000,000 – 10,000,000 AUD for pre-clinical diagnostic startups in Australia. Imagine its valuation in clinical diagnostics with your help?

Myopharm Ltd

Karinza Phoenix
Chief Executive Officer &
Executive Chair
Myopharm Ltd

Address
L 1, 60 Martin Place
Sydney, New South Wales 2000

Website
www.myopharm.com

Contact
+61 (0)2 85272453

Email
investor@myopharm.com

Company Description

Myopharm® is an FDA-IND–approved, Phase II biopharmaceutical company developing first-in-class, novel therapeutics to transform the treatment and prevention of Type 2 diabetes, a market where more than 50% of patients experience treatment failure with current therapies. In parallel, the company has initiated preclinical programs targeting Type 1 diabetes, further expanding its pipeline potential. By addressing significant unmet medical needs in diabetes care, Myopharm is strategically positioned to capture substantial market share and deliver long-term value to patients, partners, and investors.

Myopharm's lead asset, RK-01 (TriGlytza®), is a first-in-class triple-combination therapy designed for the millions of Type 2 diabetes patients who are either non-responsive to current therapies or treatment-naïve. This critical gap left by existing Type 2 diabetes drugs, including widely used GLP-1s such as Ozempic®, sees treatment failure rates exceeding 50%.

Targeting both non-responsive and treatment-naïve patients, TriGlytza® has demonstrated in preclinical models a 1.3-unit reduction in HbA1c, with additional benefits in beta-cell preservation, improved insulin sensitivity, and reductions in both subcutaneous and visceral fat. This differentiated profile positions TriGlytza® as a potential game-changer in a global diabetes market worth over $150 billion annually. Complementing this, Myopharm has partnered with Monash University (Melbourne) on a Type 1 diabetes preclinical program, with results expected in late 2025. Together, these programs create a robust, diversified pipeline with strong clinical rationale, clear competitive advantages, and significant value creation opportunities for investors.

Pipeline and Developments

Myopharm are currently working towards initiating our **Phase II Trial: RESILIENCE STUDY ClinicalTrials.gov ID NCT03686657** with the **first** patient enrolment anticipated in Q2, 2026.

- 90 adult patients in a multi-site trial in Australia
- T2DM, obese patients with inadequate glycaemic control on Metformin
- Three arms, Metformin, Low dose TriGlytza® and High dose TriGlytza®
- 24-week treatment period
- Endpoints: Demonstrated safety and TriGlytza® provides greater HbA1c % improvements in glycaemic parameters compared to metformin monotherapy

RK-01 TriGlytza® Value Proposition
The growing complexity of Type 2 diabetes has fuelled rapid demand for innovative dual and triple combination therapies. TriGlytza® is uniquely positioned in this space, targeting a multi-billion-dollar market where Metformin remains insufficient for long-term disease control. Unlike repurposed drugs, TriGlytza® combines low-dose Valsartan and Celecoxib with Metformin, addressing the inflammatory pathways driven by Prostaglandin E2, a key mediator of disease progression. With development of a comprehensive pipeline strategy underway in additional indications such as polycystic ovarian syndrome (PCOS) and LADA (Latent Autoimmune Diabetes in Adults), TriGlytza® offers a differentiated mechanism and broad therapeutic potential. Given the urgent need for new modalities to achieve sustained glycaemic control, Myopharm is positioned to deliver transformative value across diabetes and related metabolic disorders.

Key Investment Highlights

Innovative, Proprietary Asset:
- **RK01 TriGlytza®** is wholly owned by **Myopharm Limited.**
- Proprietary, custom-designed formulation with **IND approval** and **68 metabolic-related indications disclosed in global patents.**

Clinical Development:
- **Phase 2 Clinical Trial – RESILIENCE Study** (ClinicalTrials.gov ID: NCT03686657).
- First patient enrolment scheduled for **Q2 2026.**
- Targeting **treatment non-responsive Type 2 diabetes patients**, with a focus on **reducing mean HbA1c.**

Diversified Product Portfolio:
- OMNI-D: wholly-owned **Food for Special Medical Purpose (FSMP) products** for Type 2 diabetes.
- **Launched in Australia Q2 2025**, targeting pharmacy outlets.
- Supported by **35 global patents.**

Investment Opportunities

- **Raising A$3.5M** to fund Phase 2 clinical development; **A$1.7M already secured.**
- Potential **liquidity event in 2026.**
- Strategic engagement with **government funding bodies** to access non-dilutive capital, partnerships, and licensing opportunities.
- Positioned on a **high-growth trajectory**, targeting expedited **505(b)(2) regulatory pathway.**

Neuroscientific Biopharmaceuticals (ASX:NSB)

Nathan Smith
Chief Executive Officer
Neuroscientific
Biopharmaceuticals

Address
Level 1, 22 Stirling Hwy,
Nedlands, WA, 6009

Website
www.neuroscientific.com

Contact
0477 738 404

Email
nsmith@neuroscientific.com

Company Description

NeuroScientific Biopharmaceuticals (ASX: NSB) is an innovative biotechnology company developing stem cell therapies using its patented StemSmart manufacturing technology to treat patients with Crohn's disease and other severe inflammatory auto-immune disorders.

Pipeline and Developments

The StemSmart MSC product is currently being used in a special access program for fistulising Crohn's disease, along with a previously completed phase 2 clinical trial in refractory Crohn's. In addition, NSB has recently published data using StemSmart MSCs to support kidney transplantation.

Upcoming Phase 2 study in US & Australia for refractory Crohn's is planned for 2H 2026. Other indications include lung disorders and graft versus host disease. Total potential market is $35-40 billion.

Key Investment Highlights

NSB acquired the StemSmart technology in April 2025. With promising clinical trial data in refractory Crohn's disease and Mesoblast's FDA approval in December 2024, NSB's share price improved from $0.04 to $0.25 before balancing back to $0.17 currently. The organisation has a current market capitalisation near $60M and has $7.3M cash with a runway through the end of CY2026.

Investment Opportunities

In advance of our planned Phase 2 clinical trial in refractory Crohn's disease in the US and Australia, NSB will be planning to raise capital to complete this study. Planned initiation is in Q3-Q4 2026.

Polyactiva Pty Ltd

Vanessa Waddell
Chief Strategy Officer
Polyactiva Pty Ltd

Address
Unit 21, 45-47 Normanby Rd,
Notting Hill, VIC, 3168

Website
www.polyactiva.com

Contact
0412 153 524

Email
vanessa.waddell@polyactiva.com

Company Description

PolyActiva is a private venture capital funded clinical-stage ophthalmology company with the mission to become a leader in ophthalmic sustained drug delivery to improve patient outcomes and quality of life.

PolyActiva's PREZIA™ platform is a unique proprietary polymeric prodrug technology that provides precise and controlled drug delivery to the eye.

Their lead candidate, PA5108, is a biodegradable latanoprost ocular implant designed to deliver 6-months of daily dosing to patients suffering from open-angle glaucoma, removing the need for daily eye drops. Along with strong efficacy, the reliable implant biodegradation and favourable safety profile allows for repeat dosing, something no marketed implant has achieved to date.

PA5108 is currently in a phase 2b clinical study in the USA, with the registration study to commence early 2027. PolyActiva's platform is adaptable to a variety of small drug molecules, they are exploring additional opportunities to expand their pipeline to target back-of-eye indications.

Pipeline and Developments

PolyActiva's lead candidate (PA5108 Ocular Implant) for glaucoma has successfully completed a phase 2a clinical trial. PolyActiva recruited a total of 37 participants into this study. Positive results from the low dose cohort were reported in 2022 and final data on the repeat dose cohort (subjects who have received two implants, 21 weeks apart) was reported in October 2024. A phase 2b study has been initiated for PA5108 in the US, with the first patient dosed in August 2025.

PolyActiva has also initiated a Phase 1b clinical trial of a second-generation implant, designed to deliver 12 months of continuous treatment.

PolyActiva has a steroid implant in early-stage development, the implant is being developed as a treatment for diabetic macular oedema.

Key Investment Highlights

PolyActiva's implant is designed to address a significant unmet need in the U$4.5bn glaucoma market. Promising phase 2a clinical data supports use of PA5108 (latanoprost ocular implant) for chronic treatment of glaucoma.

The phase 2b 75 patient study, evaluating PA5108 against latanoprost eye drops was initiated in mid-2025, with first patient dosed in August 2025.

PolyActiva has patent protection for lead candidate PA5108 out to 2039.
PA5108 is eligible for the 505(b)(2) pathway for product registration.

PolyActiva's second generation latanoprost implant is in phase 1 studies and already funded via non-dilutive funding.

With their adaptable platform technology, PolyActiva is exploring new small molecule drugs for further ocular disease indications, opening up additional valuable markets.

Investment Opportunities

PolyActiva is Australian based, with a US subsidiary, and locally funded. PolyActiva has been funded by Venture Capital since 2012, raising over A$90m. Funding raised to date has supported the development of the technology, identification of a clinical candidates, preclinical animal testing, CMC and five clinical trials.

Additional funding will be required in late 2026 to support the Phase 3 registration trials for PA5108 and development of additional pipeline candidates. PolyActiva is considering future venture capital investment, a potential public offering or strategic partnerships to support its registration program.

Prescient Therapeutics Ltd (ASX:PTX)

James McDonnell
Chief Executive Officer
Prescient Therapeutics Ltd

Address
Suite 2, Level 11, 385 Bourke St,
Melbourne, VIC, 3000

Website
www.ptxtherapeutics.com

Contact
0431 534 910

Email
james.mcdonnell@ptxtherapeutics.com

Company Description

Prescient Therapeutics (ASX:PTX) is a clinical-stage oncology company developing novel targeted therapies. Its lead asset, PTX-100, is a first-in-class GGT-1 inhibitor now in a Phase 2a clinical study for T-cell lymphomas, with both FDA Fast Track and Orphan Drug Designations.

Beyond PTX-100, Prescient has two next-generation cell therapy platforms, OmniCAR and CellPryme, designed to enhance current CAR-T therapies and overcome their challenges.

Pipeline and Developments

Prescient Therapeutics' lead asset PTX-100, is a first-in-class GGT-1 inhibitor that disrupts the RAS pathway, which is mutated in 22% of all cancers.

A prior Phase 1b study in T-cell lymphomas showed encouraging efficacy, with 64% of patients experiencing tumour halt or shrinkage with a durable response and favourable safety. A sub-analysis of 7 evaluable relapsed and refractory Cutaneous T Cell Lymphoma (r/rCTCL) patients demonstrated a 43% overall response rate with 100% of these patients receiving clinical benefit. The duration of response was 12.4 months. There were no serious adverse events related to PTX-100. A Phase 2a study in r/rCTCL patients is underway.

Key Investment Highlights

Prescient is well funded, with $12.3m cash as of September 30, 2025. This provides funding for phase 2a progress to deliver value-creating milestones.

PTX-100's advanced clinical development represents Prescient's most significant value driver, addressing an area of high unmet need in a $1.8B T-cell lymphoma market.
PTX-100 exhibits excellent safety as well as efficacy signals exceeding that expected from standard of care treatments.

The compound has been granted Orphan Drug Designation by US FDA and Fast Track Designation, providing potential accelerated development for a shortened registration pathway and potential market exclusivity.
As the only GGT-1 inhibitor in clinical development globally, PTX-100 holds a unique competitive position targeting the RAS super-family pathway where RAS mutations are present in 22% of cancers. Additional PTX-100 sensitive RAS tumour types are being investigated.

The company benefits from an experienced Board and management team.

Investment Opportunities

PTX-100's Phase 2a clinical trial, initiated in May 2025, has created value opportunities as Prescient's lead program targeting r/rCTCL. Recruiting 40 patients globally with trial sites expanding across Australia, the United States and Europe, PTX-100's development path includes multiple study updates and regulatory milestones.

The compound's first-in-class status as the only GGT-1 inhibitor in development provides significant competitive advantages and partnership appeal. PTX-100's broad RAS pathway disruption mechanism creates expansion opportunities into additional cancer indications, potentially addressing over 20% of all cancers.

Prescient's portfolio assets, including OmniCAR universal CAR technology and CellPryme cell therapy enhancement platform, provide additional partnership and licensing opportunities that complement the primary PTX-100 program.

This combination of advanced clinical progress, regulatory advantages, and diversified asset portfolio creates multiple opportunities for strategic partnerships, licensing arrangements, or acquisition interest. Investors and collaborators interested in supporting the ongoing development program are welcome to engage with us.

QBiotics Group Ltd

Ebru Davidson
General Counsel
QBiotics Group Ltd

Address
Po Box 42, Toowong Bc, QLD, 4066

Website
www.qbiotics.com

Contact
0401 763 560

Email
jebru.davidson@qbiotics.com

Company Description

QBiotics is a clinical-stage life sciences company developing small molecules for oncology and wound healing.

Our lead asset, tigilanol tiglate, rapidly destroys solid tumours with a single injection. It is currently in Phase IIa human trials for soft tissue sarcomas—with FDA Orphan Drug Designation—and head and neck cancers. A veterinary formulation, STELFONTA®, is already approved and distributed globally by Virbac for treating canine mast cell tumours, validating the technology.

Our second candidate, EBC-1013, is a topical drug that accelerates the healing of chronic wounds and is currently in a Phase I clinical trial.

Pipeline and Developments

QBiotics' pipeline is anchored by tigilanol tiglate, a lead asset in interventional oncology showing compelling Phase IIa data, including an 80% response rate in injected tumours in soft tissue sarcoma (STS) patients, where 8 out of 10 patients experienced complete or partial injected tumour reductions.

Building on this success, a Phase IIa expansion in STS is currently open at Memorial Sloan Kettering Cancer Center. STS's limited treatment options present a possible accelerated pathway to registration. Tigilanol tiglate also holds potential for broad application across several solid tumours, including early and late-stage settings, and in combination with current cancer therapies.

The Company's second asset, EBC-1013 is currently in Phase I clinical trials for venous leg ulcers. Underpinning QBiotics' current programs is the Company's epoxytiglianes platform. Tigilanol tiglate and EBC-1013 are two of three interlinked programs from this platform, with a third, next-generation antibiotic program currently in lead selection.

Key Investment Highlights

- Scalable, small molecule platform enables multi-asset pipeline opportunity across various indications.
- Two clinical stage assets with multiple near-term catalysts.
- Compelling Phase II data from STS trial with 80% response rate in injected tumours.
- Incoming investors benefit from substantial capital already invested into drug development.
- Large and valuable addressable markets in oncology AND wound healing.
- Proven efficacy in veterinary applications presents regulatory and commercial validation in human applications.
- Existing collaborations with leading global organisations.
- Board refreshed - Board with big Pharma background with M&A and commercial launch experience.

Investment Opportunities

QBiotics offers a compelling investment opportunity with its multi-asset pipeline and platform-driven growth. Its lead drug, tigilanol tiglate, provides rapid tumour destruction with promising Phase IIa results, FDA Orphan Drug Designation, an expansion trial at Memorial Sloan Kettering, and a possible accelerated pathway to registration.

Our scalable epoxytiglianes platform has also produced EBC-1013, a wound therapy with broad applicability for chronic conditions.

The investment is de-risked by the successful veterinary commercialisation of tigilanol tiglate (marketed as STELFONTA®), which provides crucial regulatory and commercial validation. Both assets target valuable oncology and wound care markets where there is high unmet need.

S2n.bio

Dr. Brendon Boot
Chief Executive Officer
S2n.bio

Address
Level 17, 123 Pitt St, Sydney, NSW, 2000

Website
www.s2n.bio

Contact
0493 518 670

Email
bboot@skin2neuron.org

Company Description

S2N is pioneering autologous cell therapies for Alzheimer's and other neurological diseases. We use unipotent precursor cells from hair follicles that exclusively become neurons, safely reconstituting lost hippocampal networks to durably restore memory function. In veterinary clinical trials with pet dogs—the only valid Alzheimer's model—we demonstrated a 9 standard deviation increase in synapses and profound cognitive improvements. Our approach avoids pluripotency and gene modification, ensuring minimal cancer risk and a simple regulatory path. With a scalable, low-cost manufacturing process, our platform is also being differentiated for Parkinson's, epilepsy, and Huntington's disease.

Pipeline and Developments

S2N's technology has the potential to improve the welfare of millions worldwide with Alzheimer's, Parkinson's and epilepsy. If they replicate their pre-clinical findings in the clinic, S2N's therapies will bring about profound societal change: millions of patients in nursing homes will return to independent living. Dopamine-producing cells for S2N's second indication, Parkinson's disease, have been transferred to Massachusetts General Hospital, for head-to-head testing against MGH's own product in a widely accepted rat model. If positive data, this will be a significant value inflection for the company. For context, Bayer acquired BlueRock Therapeutics for US$1B based on similar preclinical data and before their IND was granted.

Key Investment Highlights

S2N is steadily advancing toward its mission of delivering breakthrough cell therapies for neurological diseases—and doing so with strong investor support, clinical and research momentum, and a deepening pool of talent. S2N has raised $12.5m of investor capital from key Australian (Synthesis Bioventures, KPRx, Artesian) and international venture groups (Psymed, Termeer). S2N is the first Australian biotech to receive a strategic investment by Eli Lilly and Company. S2N has received $5.5m in non-dilutive funding from The NSW Biosciences Fund, Cureator+ (with an additional $2.5m available upon success) and as part of the SMART-CRC program. We have selected our manufacturing partner and will begin tech transfer in H2 2025. S2N are on track to commence an External Control Study in H1 2026 and to file for ethics approval for their first-in-human trial in H1 2027.

Investment Opportunities

S2N seeks $6.0m in additional funding for our A round at an attractive valuation to bring our Alzheimer's program to end of First-In-Human trials and to advance our Parkinson's program to preclinical PoC. Once the A round is complete, S2N will raise additional funds to unlock significant value in our Parkinson and epilepsy programs.

Terra Australis Pharmaceuticals Pty Ltd

Todd Robinson
Chairman
Terra Australis Pharmaceuticals

Address
Level 5, 169 Pirie Street,
Adelaide, SA, 5000

Website
www.australispharma.com

Contact
+1 336 456 8972

Email
trobinson@australispharma.com

Company Description

Terra Australis Pharmaceuticals PTY Ltd. is a global biopharmaceutical company deeply driven to bring new therapies to cancer patients in need.Our initial portfolio of promising therapies was naturally discovered on Kangaroo Island originating from bee propolis and later traced back to a plant source Our lead compound, AUS_001 is being developed by Terra Australis Pharmaceuticals PTY Ltd to treat very challenging cancers with limited treatment options, including pancreatic, GBM and pediatric high-grade gliomas such as DMG/DIPG (and even brain metastases).

Pipeline and Developments

AUS_001 is the current lead compound (with 4 more derivatives in the pipeline). It a microtubule destabilizing agent (MTA class) that leads to cancer cells growth arrest and triggers programmed cell death (apoptosis), thus helping to eliminate the cancer.

AUS_001 has demonstrated very encouraging pre-clinical efficacy and safety. In-vitro, AUS_001 exerts high potency against 24 types of cancer with an exceptional safety margin compared to all other MTAs in its class as well as to most chemotherapeutics. It takes on average, about 20 times more AUS_001 concentration to harm healthy cells compared to cancer cells. In vivo, AUS_001 has demonstrated efficacy in 7 different models to date, as well as several brain cancer 3D ex vivo models. Given that AUS_001 crosses the blood brain barrier, this presents an opportunity for AUS_001 to be used for the treatment of primary brain cancers as well as brain metastases. From a safety standpoint, the predictive toxicology data are exceptional, compared to peers. AUS_001 also does not cause myelosuppression in immuno-competent mice.

Interestingly, an increase in the number of neutrophils was observed in a repeat dose toxicity study in mice.

AUS_001 is currently being developed as an oral formulation which provides ease of dosage for patients. No emetic response was observed in ferrets which supports the viability of an oral formulation. We have completed dose range finding studies in mice and rats to inform Good Laboratory Practices (GLP) toxicology pre-clinical enabling studies, which should be complete in January 2026.

Key Investment Highlights

Terra Australis has raised over $30 Million through private fund raising and we have no third-party debt on our balance sheet. These funds have been used to: perform extensive medicinal chemistry (resulting in over 5,000 analogues and derivatives); characterize the mechanism of action; conduct pharmacokinetics/ pharmacodynamics studies; predictive toxicology screening; in-vitro and in-vivo efficacy; and initiate the GLP toxicology studies. In addition, we have developed a scalable manufacturing process to synthesize AUS_001.

AUS_001 will be ready for Phase 1 studies in Q1 2026, following completion of GLP toxicology studies. The Phase 1 dose escalation study will be completed in Australia with plans for expansion cohorts in Australia and the US once the Maximum Tolerated Dose (MTD) is established.

Orphan Drug Designation was issued for AUS_001 for malignant gliomas in February, 2025 and Rare Pediatric Disease Designation was issued for AUS_001 for pediatric high-grade gliomas in March, 2025 by the FDA. In addition, as of July 15, 2025, the FDA supports our nonclinical plan intended to back the clinical development of AUS_001, pursuant to our pre-IND meeting request submitted in May 2025.

Investment Opportunities

Requesting A$50mm investment in this round (likely final) at a TBD valuation level. These funds would be used to further advance the clinical studies for AUS_001 – also for other cancers (e.g.- other childhood, Ewings Sarcoma, TNBC, etc.) that would be needed for regulatory approvals.

Tiba Biotech

Dr. Jas Chahal
Chief Scientific Officer
Tiba Biotech

Address
1/46 Cliffbrook Parade,
Clovelly, NSW, 2031

Website
www.tiba.bio

Contact
0425 289 396

Email
chahal@tiba.bio

Company Description

Tiba's next-generation technology overcomes key challenges with existing RNA therapies: inflammation, stability, and targeted delivery. Our platform enables repeatable, low-inflammation dosing, expanding RNA use into high-value human markets like oncology and cardiovascular disease, as well as animal health.

Unlike other platforms, our formulations are stable at room temperature, simplifying global distribution. Most transformative is our ability to achieve organ-specific targeting beyond the liver, unlocking new therapeutic opportunities in the heart, lungs, and central nervous system.

By combining safety, accessibility, and precision, our platform is positioned to capture meaningful market share and set the standard for RNA-based medicine.

Pipeline and Developments

Tiba Biotech is advancing a next-generation RNA delivery platform validated across human and animal health. In animal vaccines, we secured a fully funded 5-year R&D partnership with NSW DPIRD for key livestock diseases, retaining all commercial rights. Our platform has already delivered preclinical vaccines for numerous viral targets, demonstrating broad versatility.

In human health, we are progressing novel therapeutics for ARDS, ischemic heart disease, and pancreatic cancer. Comparative studies show our system outperforms Moderna's with reduced inflammation and improved organ targeting. With competitive funding from global health bodies including NIH, BARDA, and CEPI, Tiba's milestones showcase a validated, differentiated platform positioned to transform RNA medicine.

Key Investment Highlights

Tiba Biotech has built strong momentum through competitive grants and strategic investment. To date, we have secured over AUD 22 million in committed, non-dilutive grant funding from leading global organisations like NIH, BARDA, and CEPI, providing significant external validation and accelerating our programs. This is complemented by AUD 7 million in equity from a strategic investor base, including a specialist venture fund and a global CRO.

We are now seeking AUD 1.5 million in convertible notes to bridge into a AUD 9 million Series A round. This funding will accelerate the clinical development of our human health pipeline and unlock near-term commercial opportunities.

Investment Opportunities

Tiba offers investors a unique opportunity to participate in the next generation of RNA therapeutics and vaccines.

We are currently raising AUD 1.5 million in convertible debt, structured at an attractive valuation entry point for smaller investors who wish to secure a position before larger institutional backers fund our upcoming Series A. This round provides early investors with preferential terms and the chance to capitalize on significant near-term value creation.

The planned AUD 9 million Series A will accelerate the clinical development of our human health programs—including novel therapeutics for ARDS, ischemic heart disease, and pancreatic cancer—and advance precision RNA vaccines for global health and animal health markets.

With proven platform advantages over first-generation mRNA systems, strong preclinical validation, and a board committed to an investor-friendly pre-money valuation, Tiba represents a highly differentiated and scalable opportunity in one of the fastest-growing sectors in biotechnology.

Notes

Notes

Australia's Biggest Week in Medtech

is coming to Western Australia next

May 19-21 2026

Host State Partners

GOVERNMENT OF WESTERN AUSTRALIA

BUSINESS EVENTS PERTH

AusBiotech AusMedtech 2026

AusBiotech MedtechInvest 2026

Mark your calender

this is a conference you don't want to miss.

AusBiotech

Where life science leaders thrive

Website
www.ausbiotech.org

Contact
+61 (0)419 394 097

Email
admin@ausbiotech.org

Follow @AusBiotech for the latest updates #AusBiotech